Peter Lin
Overview
Explore the profile of Peter Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
141
Citations
2439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Madero M, Levin A, Ahmed S, Carrero J, Foster B, Francis A, et al.
Ann Intern Med
. 2025 Mar;
PMID: 40063957
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease...
2.
Nair-Menon J, Kingsley C, Mesnaoui H, Lin P, Wilson K, Rohrer B, et al.
Res Sq
. 2025 Mar;
PMID: 40034449
The RNA interference (RNAi) machinery is a key cellular mechanism catalyzing biogenesis and function of miRNAs to post-transcriptionally regulate mRNA expression. The RNAi machinery includes a set of protein complexes...
3.
Emmett L, Subramaniam S, Crumbaker M, Joshua A, Sandhu S, Nguyen A, et al.
Lancet Oncol
. 2025 Feb;
26(3):291-299.
PMID: 39956124
Background: Interim analysis of the ENZA-p trial showed improved prostate-specific antigen (PSA) progression-free survival with the addition of lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 to enzalutamide as first-line treatment of metastatic...
4.
Azad A, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt A, et al.
Lancet Oncol
. 2024 Sep;
25(10):1267-1276.
PMID: 39293461
Background: Lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 improves survival and quality of life in patients with metastatic castration-resistant prostate cancer, but whether it confers a benefit in hormone-sensitive disease is unknown....
5.
Lin P, Argon N, Cheng Q, Evans C, Linthicum B, Liu Y, et al.
Health Serv Insights
. 2024 Sep;
17:11786329241277724.
PMID: 39247491
Background/objectives: The race-sex differences in emergency department (ED) disposition decisions have been reported widely. Our objective is to identify demographic and clinical subgroups for which this difference is most pronounced,...
6.
Kaplan A, Babineau A, Hauptman R, Levitz S, Lin P, Yang M
Front Med (Lausanne)
. 2024 Aug;
11:1416163.
PMID: 39165372
Chronic obstructive pulmonary disease (COPD) is a highly prevalent yet under-recognized and sub-optimally managed disease that is associated with substantial morbidity and mortality. Primary care providers (PCPs) are at the...
7.
Faisal H, Lim W, Dattagupta A, Lin P, Gupta R, Lai E, et al.
Games Health J
. 2024 Aug;
PMID: 39109450
The aim of the current pilot study was to evaluate the usability, acceptability, and tolerability of virtual reality (VR)-based cognitive stimulation exercises (CSEs) in healthy young versus old populations before...
8.
Nindra U, Lin P, Becker T, Roberts T, Chua W
J Med Imaging Radiat Oncol
. 2024 Apr;
68(4):412-420.
PMID: 38632711
Prostate cancer remains one of the leading causes of cancer-related death in the world. There have been significant advances in chemotherapy, hormonal therapy and targeted therapy options for patients with...
9.
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua A, Weickhardt A, et al.
Lancet Oncol
. 2024 Apr;
25(5):563-571.
PMID: 38621400
Background: Enzalutamide and lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data...
10.
Levin A, Ahmed S, Carrero J, Foster B, Francis A, Hall R, et al.
Kidney Int
. 2024 Mar;
105(4):684-701.
PMID: 38519239
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) updates the KDIGO 2012 guideline and has been developed with...